NEOGAP Therapeutics AB
PrivateLast Round
Early Funding
Feb 11, 2026
Est. Valuation
$23M
Total Funding Raised
$13.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
NEOGAP Therapeutics AB is a biotechnology company that develops personalized cancer immunotherapy designed to precisely target and eliminate cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NEOGAP Therapeutics AB Comparables
Compare NEOGAP Therapeutics AB with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CuraCell Holding AB | 83% | |
| Enara Bio | 80% | |
| Geneos Therapeutics | 79% |
NEOGAP Therapeutics AB Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Feb 11, 2026 | ||||
| Grant | Nov 5, 2025 | ||||
| Grant | Feb 26, 2025 | ||||
| Grant | Mar 26, 2024 | ||||
| Grant | Nov 9, 2023 | ||||
VC Round | Nov 9, 2023 |
Key People
Founding team and executive leadership
NEOGAP Therapeutics AB Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant |
| Eurostars SME programme | Grant |
| Vinnova | Grant |
| Sciety | VC Round, Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 11, 2026
Raised $9.8M in early funding.
- Feb 11, 2026
Partnered with NorthX Biologics to advance cell therapy manufacturing.
NEOGAP Therapeutics AB Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about NEOGAP Therapeutics AB's valuation, stock price, and market status.
Is NEOGAP Therapeutics AB a public or private company?
NEOGAP Therapeutics AB is a private company.
What is the current stock price of NEOGAP Therapeutics AB?
NEOGAP Therapeutics AB is a private company, so its shares have no public market price. Caplight tracks NEOGAP Therapeutics AB's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NEOGAP Therapeutics AB worth (valuation)?
NEOGAP Therapeutics AB's valuation is estimated at $23.0M based on funding round data.
Can I buy NEOGAP Therapeutics AB stock?
NEOGAP Therapeutics AB shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NEOGAP Therapeutics AB's last funding round?
NEOGAP Therapeutics AB's most recent funding round was Early Funding on February 11, 2026.
Who are the main investors in NEOGAP Therapeutics AB?
Key investors in NEOGAP Therapeutics AB include Sciety.
Will NEOGAP Therapeutics AB IPO soon?
No public IPO plans have been announced for NEOGAP Therapeutics AB.
How can I track NEOGAP Therapeutics AB secondary market activity?
Caplight tracks bids, offers, and trades in NEOGAP Therapeutics AB's shares on secondary markets.